
















542Immunosuppressive Cytokine Gene Polymorphisms
and Outcome after Related and Unrelated
Hematopoietic Cell Transplantation in
a Chinese Population
Haowen Xiao,1,2 Weijie Cao,1 Xiaoyu Lai,1 Yi Luo,1 Jimin Shi,1 Yamin Tan,1 Jingsong He,1
Wanzhuo Xie,1 Xiaojian Meng,1 Weiyan Zheng,1 Gaofeng Zheng,1 Xiaoyan Han,1 Lai Jin,1
Lifei Zhang,1 Yingjia Wang,1 Xiaohong Yu,1 Zhen Cai,1 Maofang Lin,1 Xiujin Ye,1 He Huang1Cytokine gene polymorphisms can affect the outcome of allogeneic hematopoietic stem cell transplantation.
We analyzed 6 single nucleotide polymorphisms in 3 immunosuppressive cytokine genes, TGFb12
509(C.T), 1869(T.C), TGFb1 receptor II (TGFb1RII) 11167(C.T, codon389 AAC/AAT), and IL-
1021082(A.G),2819(T.C),2592(A.C), in a cohort of 138 pairs of recipients and their unrelated donors
and a second cohort of 102 pairs of recipients and their HLA-identical sibling donors. TGFb12509 T/T ge-
notype in the donors or Tallele-positivity in the recipients was associated with a significant protective effect
against acute graft-versus-host disease (aGVHD) and grades II–IVaGVHD in the unrelated transplantation co-
hort. In the combined cohort, multivariate analysis confirmed that donors with the TGFb1-509 T/T genotype
also conferred protection against the risk of aGVHD and grades II–IV aGVHD. In both the unrelated trans-
plantation cohort and the sibling transplantation cohort, the IL-102819 C/C and2592 C/C genotypes in ei-
ther recipients or donors were significantly associated with a higher incidence of aGVHD. In the combined
cohort, the IL-10 promoter haplotype polymorphisms at positions 21082, 2819, and 2592 influenced the
occurrence of aGVHD and death in remission. Recipients without the A-T-A haplotype or those transplanted
from donors without the A-T-A haplotype had a higher incidence of aGVHD than those who were A-T-A ho-
mozygotes or heterozygotes. Estimates for death in remission showed a clear advantage for recipients trans-
planted from donors with the A-T-A haplotype. In multivariate analysis, recipients without the A-T-A IL-10
haplotype had a higher risk of aGVHD (relative risk [RR] 5 0.764; 95% confidence interval [CI]: 0.460-
1.269; P5.096) and grades II–IV aGVHD (RR5 0.413; 95% CI: 0.245-0.697; P5.001). These results provide
the first report of an association between TGFb1, TGFb1RII, and IL-10 polymorphic features and outcome of
allo-HSCT in a Chinese population, and suggest an interaction between TGFb12509 genotypes and IL-10
promoter haplotype polymorphisms at positions 21082, 2819, and 2592 and the risk of aGVHD.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is an effective treatment for hematopoi-
etic malignancies, as well as for immune deficiencies
and metabolic disorders. In patients undergoing allo-
HSCT, the toxicity of the conditioning regimen, in-
fectious complications, and the alloimmune response
mediated by donor lymphocytes are all associated
with the generation of cytokines. Acute graft-versus-
host disease (aGVHD) remains a significant cause of
treatment-related mortality and morbidity following
allo-HSCT. The incidence of aGVHD ranges from
35% to 45% in recipients after HLA fully matched sib-
ling transplantation, to 60% to 80% in recipients after
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transplantation [1]. aGVHD can be fatal in 15% to
40% of cases [2]. The imbalance between Th1 cyto-
kines such as tumor necrosis factor (TNF)a, interferon
(IFN)g, and interleukin (IL)1, and Th2 cytokines such
as IL-4, IL-10, and the immunoregulatory cytokine,
transforming growth factor-b (TGFb), has been sug-
gested to play an important role in the development
of aGVHD.
TGFb and IL-10 are pleiotropic regulatory cyto-
kines in the immune system, and both play key roles in
the function of regulatory T cells (Treg). Furthermore,
IL-10 facilitates the regulatory function of TGFb [3-5].
Clinical data and data from animal models suggest that
TGFb and IL-10 can suppress aGVHD [6,7]. The
potential to generate cytokines may be associated with
polymorphic features of the cytokine-encoding genes.
Many cytokine gene polymorphisms, such as those for
TNFa, IL-10, and IFNg, have been investigated over
the last 10 years for their potential roles in the occur-
rence and severity of GVHD, as well as for their contri-
bution to overall treatment-relatedmortality, infectious
episodes, and overall survival (OS) [8,9]. However, very
few studies have simultaneously studied sibling donor
and URD transplantation, and there are no data in the
Chinese population. The present study was designed
to test the influence of polymorphisms of the
immunosuppressive cytokine genes for TGFb and IL-
10on theoutcomeof allo-HSCTina cohort of 138pairs
of recipients and their URDs, and in a second cohort of
102 pairs of recipients and their HLA-identical sibling
donors.MATERIALS AND METHODS
Characteristics of the HSCT Patient Group
The entire study population consisted of 240 pairs
of transplant recipients and their donors who were
transplanted from January 2001 to March 2009 in
our Bone Marrow Transplantation Unit. The inci-
dences of aGVHD, chronic GVHD (cGVHD) and
OS were analyzed in relation to IL-10, TGFb1, and
TGFb1 receptor II (TGFb1RII) gene polymorphisms
(Table 1). All the patients and their donors were of
Chinese origin. The study was approved by the local
ethics committee. All the patients and donors gave
their written informed consent.
Low-resolution HLA typing had been performed
for HLA-A, -B, and -DRB1 in sibling transplantation
and high-resolution DNA typing for HLA-A, -B, -C,
-DRB1, and -DQB1 in URD transplantation.
The main myeloablative (MA) conditioning regi-
mens used were busulfan/cyclophosphamide (BuCy)
without total body irradiation (TBI); reduced-
intensity conditioning regimens (RIC) were
predominantly fludarabine-based combinations with-out irradiation. Both in the unrelated and sibling trans-
plantation cohorts, the patients received the same
GVHD prophylaxis consisting of cyclosporine A,
a short-term methotrexate (MTX), and mycopheno-
late mofetil (MMF).
The study was divided into 2 phases and involved
2 separate cohorts. The initial cohort consisted of
138 pairs of recipients and their URD. We used
this cohort to screen for an association between
GVHD and IL-10, TGFb1, and TGFb1RII gene
polymorphisms. The second cohort included 102
pairs of recipients and their HLA-identical sibling
donors. This cohort was used for confirmatory anal-
ysis. There were significant differences between these
groups in terms of the patients’ ages, transplant mate-
rial, cumulative incidence of aGVHD, cumulative
incidence of death in remission, and OS (Table 1).
A final analysis of clinical end points included both
cohorts.
DNA Extraction
Genomic DNA was extracted from peripheral
blood samples obtained from recipients and donors
before transplantation using a salting-out method
with a commercial DNA extraction kit (Dynal Biotech,
Brown Deer, WI), following the manufacturer’s rec-
ommendations. DNA was quantified by spectropho-
tometry.
Analysis of TGFb1, TGFb1RII, and IL10
Polymorphisms
The IL-10-1082(A.G), 2819(T.C), 2592
(A.C), TGFb12509(C.T), 1869 (T.C), and
TGFb1RII11167(C.T, codon389 AAC/AAT) single
nucleotide polymorphisms (SNPs) were determined
by multiplex SNaPshot technology (according to pre-
viously described methods [10-12]), using an ABI
fluorescence-based assay allelic discrimination method
(Applied Biosystems, Bedford, MA).
The primers for polymerase chain reaction (PCR)
amplification and SNaPshot extension reactions were
both designed to be aligned with the NCBI sequence
databases using Primer3 software. The extension
primer was designed to anneal immediately adjacent
to the nucleotide at the mutation site, on either the
sense or antisense DNA strand (Table 2).
PCR was carried out in a total volume of 10 mL
containing 50 ng genomic DNA, 0.1 mM of each
primer, 0.3 mM each of dATP, dCTP, dTTP, and
dGTP, 1 unit of HotStarTaq polymerase (Qiagen,
Chatsworth, CA), 4 mL of 1 buffer, and 3.0 mM
MgCl2. The samples were put through 30 to 40 cycles
of denaturation at 94C, annealing at specific primer
temperatures, elongation at 72C, and a final extension
at 72C. PCR product amplification was verified by
running 5 mL of product on a 2% agarose gel. The
Table 1. Patients, Disease, and Transplantation Characteristics in the First and Second Cohorts
Characteristics Unrelated Transplant (n 5 138) Sibling Transplant (n 5 102) P-Value
Age (median, range), years 24 (1050) 32 (14-52) <.001
Donor-recipient sex, n (%)
Female-male 35 (25.4) 33 (32.4) .249
Other 103 (74.6) 69 (67.6)
Reason for transplantation, n (%)*
Nonmalignant disease 6 (4.3) 6 (5.9) .766
Low-risk cancer 117 (84.8) 90 (88.2) .57
High-risk cancer 15 (10.9) 6 (5.9) .248
Transplant material, n (%)
Bone marrow 56 (40.6) 12 (12.8) <.001
Peripheral blood stem cells 82 (59.4) 90 (87.2)
HLA matching
Matched 96 (69.6) 102 (100%) <.001
Mismatched 42 (30.4) 0
Conditioning regimen, n (%)
Myeloablative 120 (87) 89 (87.3) .946
RIC 18 (13.0) 13 (12.7)
Cumulative incidence of aGVHD % %
Grade 0 31.9 76.5 <.001
Grade I 24.6 10.8 .007
Grade II 32.6 11.8 .003
Grade III 2.2 1.0 <.001
Grade IV 8.7 0 <.001
Cumulative incidence of cGVHD, (%) 32.6 33.3 .933
Cumulative incidence of clinical extensive cGVHD, (%) 15.9 10.8 .343
Cumulative incidence of relapse, (%) 21.0 19.6 .872
Cumulative incidence of death in remission, (%) 24.6 9.8 .004
Cumulative overall survival, % 58 74.5 .009
RIC indicates reduced-intensity conditioning; cGVHD, chronic graft-versus-host disease; aGVHD, acute graft-versus-host disease.
*Nonmalignant diseases included aplastic anemia, myelodysplastic syndrome, and paroxysmal nocturnal hematuria. Low-risk cancers included acute lym-
phoblastic leukemia (ALL), acute myelogenous leukemia (AML), and non-Hodgkin lymphoma (NHL) in complete remission (CR) and chronic myelog-
enous leukemia (CML) in chronic phase. High-risk cancers included ALL, AML, and NHL in relapse; CML in other than chronic phase; multiple myeloma,
and Hodgkin’s disease.
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the ABI SNaPshot protocol, using primers designed
for fluorescence dideoxynucleotide termination. SNP
analysis was carried out using an ABI3130 genetic
analyzer. Genotypes were determined automatically
using Genemapper4.0 software (Applied Biosystems).
Genotyping was confirmed by sequencing in 10%
of randomly selected samples, as a quality control
measure.Statistical Analyses
Only patients who had successful engraftment and
survived more than 30 days were included in the anal-
ysis of aGVHD.Univariate analyses of the distribution
of IL-10, TGFb1, and TGFb1RII genotypes in pa-
tients with and without aGVHD and cGVHD were
performed using Fisher’s exact tests. The incidences
of relapse, death in remission, and survival were esti-
mated using the Kaplan-Meier method, and the gener-
alized Wilcoxon test was used to analyze the
differences. The Cox proportional hazard model was
applied to multivariate analysis of the effects of these
characteristics on HSCT outcome. Statistical analysis
was performed using SPSS software version 16.0. All
probability values were 2 sided. A value of P \ .05
was considered to be statistically significant, and valuesof P between .05 and .1 were considered to be indica-
tive of a trend.RESULTS
Polymorphisms of TGFb1, TGFb1RII, and IL-10
in the First and Second Cohorts
In our study, the frequencies of the TGFb1,
TGFb1RII, and IL-10 genotypes in recipients and do-
nors were almost equal, and were consistent with pre-
viously reported results for the Chinese population
and with the NCBI SNP databases. There were also
no significant differences in the distribution of
TGFb1, TGFb1RII, and IL-10 genotypes in the first
URD transplantation cohort and second sibling trans-
plantation cohort (Table 3). No significant deviations
from the Hardy-Weinberg expected frequencies of
these genotypes were observed in either donors or
recipients (data not shown).
Association of TGFb1, TGFb1RII, and IL-10
Gene Polymorphisms with aGVHD in the First
Cohort
In the first cohort consisting of 138 pairs of recip-
ients and their unrelated donors (Table 4), the
TGFb12509 T allele in either recipients or donors
was significantly associated with a lower incidence of
Table 2. Primers Sequences Used in the SNaPshot Reaction
Mutation Position PCR Amplification Primers Extension Primers
for IL10








2592 A>C (rs1800872) R TTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTCCAGAGACTGGCTTCC TACAG
for TGFb1
2509 C>T (rs1800469) F GCAGGGTGTTGAGTGACAGG
R GAGGGTGTCAGTGGGAGGAG
R TTTTGGGCAACAGGACACCTA
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aGVHD and grades II–IV aGVHD in T allele-
positive recipients were 63.1% and 36.9%, respec-
tively, in contrast to 82.9% and 62.9%, respectively,
in C/C genotype recipients (P5 .036, P5 .01, respec-
tively). In recipients transplanted from T/T genotype
donors, the incidences of aGVHD and grades II–IV
aGVHD were 52.9% and 20.6%, respectively, in con-
trast to 73.1% and 51.0%, respectively, with other
genotypes (P 5 .035, P 5 .003, respectively).
When the association of IL-10 genotypes with
aGVHD was examined, donors or recipients with IL-
10–819C/C genotype were associated with a higher in-
cidence of aGVHD in recipients compared with T
allele-positive donors or recipients (donor side: 85.7%Table 3. Distribution of TGFb1, TGFb1RII, and IL10 Genotypes
Transplantation Cohorts
Donor Type
Genotype Unrelated Cohort n (%) Sibling Cohort n (%) P-
TGFb12509 >
C/C 32 (23.2) 34 (33.3)
T/C 72 (52.2) 53 (52)
T/T 34 (24.6) 15 (14.7)
TGFb1+869 >
T/T 30 (21.7) 31 (30.4)
C/T 71 (51.4) 54 (52.9)
C/C 37 (26.8) 17 (16.7)
TGFb1RII +1167 >
C/C 69 (50.0) 57 (55.9)
T/C 52 (37.7) 37 (36.3)
T/T 17 (12.3) 8 (7.8)
IL10-1082 >
A/A 121 (87.7) 91 (89.2)
G/A 14 (10.1) 11 (10.8)
G/G 3 (2.2) 0 (0)
IL102819 >
T/T 60 (43.5) 48 (47.1)
T/C 50 (36.2) 39 (38.2)
C/C 28 (20.3) 15 (14.7)
IL10-592 >
A/A 57 (41.3) 48 (47.1)
A/C 54 (39.1) 39 (38.2)
C/C 27 (19.6) 15 (14.7)
The differences of the distribution of TGFb1, TGFb1RII, and IL-10 genotypes in
tation cohort were performed using Fisher’s exact tests.versus 63.6%, P 5 .025; recipient side: 87.5% versus
64%, P 5 .03, respectively). A similar association was
observed for the IL-102592 C/C genotype in recipi-
ents or donors compared with A allele-positivity (P\
.05). Furthermore, the IL-10–819 C/C or 2592 C/C
genotypes in either recipients or donorswere both asso-
ciated with a higher incidence of grades II–IV aGVHD
(IL102819C/Cgenotype in the donor sideP5 .054, in
the recipient side P\ .001; IL102592C/Cgenotype in
the donor side P5 .084, in the recipient side P5 .001).
No significant associations between TGFb11869,
TGFb1RII11167, or IL-1021082 genotypes in either
recipients or donors and aGVHD were detected.
HLA allele mismatching is the main cause of
aGVHD development. To distinguish between thein the Donors and Recipients in the Unrelated and Sibling
Recipient Type
Value Unrelated Cohort n (%) Sibling Cohort n (%) P-Value
.05 >.1
35 (25.4) 36 (35.3)
66 (47.8) 47 (46.1)
37 (26.8) 19 (18.6)
.05 >.05
31 (22.5) 33 (32.4)
68 (49.2) 51 (50)
39 (28.3) 18 (17.6)
.1 >.1
76 (55.1) 55 (53.9)
49 (35.5) 38 (37.3)
13 (9.4) 9 (8.8)
.1 >.1
117 (84.8) 90 (88.2)
18 (13.0) 11 (10.8)
3 (2.2) 1 (1.0)
.1 >.1
56 (40.6) 39 (38.2)
58 (42.0) 45 (44.1)
24 (17.4) 18 (17.6)
.1 >.1
56 (40.6) 45 (44.1)
60 (43.5) 40 (39.2)
22 (15.9) 17 (16.7)
the first unrelated transplantation cohort and second sibling transplan-
Table 4. Association of Cytokine Gene Polymorphisms and aGVHD in the First Cohort of Total and HLA-Matched Recipients and
Unrelated Donors
Donor Type Recipient Type
Genotype Incidence of aGVHD(%) P-Value
Incidence of
II-IV aGVHD(%) P-Value Incidence of aGVHD(%) P-Value
Incidence of
II-IV aGVHD(%) P-Value
Total cohort (n 5 138)
TGFb12509
T/T 52.9 .035 20.6 .003 T+ 63.1 .036 36.9 .01
T/C+C/C 73.1 51.0 CC 82.9 62.9
TGFb1+869
C/C 56.8 .1 35.1 .251 65.0 .688 37.5 .45
T/C+T/T 72.3 46.5 69.4 45.9
TGFb1RII +1167
C/C 75.0 .143 40.5 .494 63.2 .268 40.3 .489
T/C+T/T 62.2 46.9 73.3 47.5
IL10-1082
A/A 69.4 .411 43.8 1.0 65.8 .210 41.5 .331
G/A+G/G 58.8 41.2 81.0 55.0
IL10-819
C/C 85.7 .025 60.7 .054 87.5 .03 79.2 <.001
C/T+T/T 63.6 39.1 64.0 36.0
IL10-592
C/C 85.2 .039 59.3 .084 86.4 .049 77.3 .001
C/A+A/A 64.0 39.6 64.7 37.1
HLA-matched (n 5 96)
TGFb1-509
T/T 51.9 .154 18.5 .019 T+ 59.7 .138 31.9 .087
T/C+C/C 69.6 44.9 CC 79.2 54.2
IL10-819
C/C 87.5 .045 56.2 .09 80.0 .243 66.7 .018
C/T+T/T 60.0 33.8 61.7 32.1
IL10-592
C/C 86.7 .076 53.3 .245 78.6 .366 64.3 .036
C/A+A/A 60.5 34.6 62.2 32.9
aGVHD indicates acute graft-versus-host disease.
Univariate analyses of aGVHD and cytokine genotype by Fisher’s exact tests. P-values <.1 are given in bold font.
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gene polymorphisms, high-resolution HLA-A, -B,
-C, -DRB1, and -DQB1 allele-matched cases (n 5
96) were analyzed (Table 4). In this analysis, we found
similar trends. TGFb12509 T/T genotype in the do-
nors or T allele-positivity in the recipients was also as-
sociated with a lower incidence of grades II–IV
aGVHD (donor side: P 5 .019; recipient side: P 5
.087). The IL-102819 C/C or 2592 C/C genotypes
in donors were associated with a higher incidence of
aGVHD and in recipients with a higher incidence of
grades II–IV aGVHD.
Association of TGFb1, TGFb1RII, and IL-10
Gene Polymorphisms with aGVHD in the
Second Cohort
To distinguish between the effects of the com-
bined influence of other genetic disparities and those
of cytokine gene polymorphisms, the TGFb12509,
IL-102819, and IL-102592 polymorphisms that
showed a significant association with the incidence of
aGVHD in the unrelated transplantation cohort
were confirmed in a second cohort consisting of 102
pairs of recipients and their HLA-identical sibling do-
nors (Table 5). The TGFb12509 T/T genotypeshowed a protective effect against aGVHD, although
the association was not significant. The IL-102819
C/C in either recipients or donors and IL-102592
C/C genotypes in donors were both significantly asso-
ciated with a higher incidence of aGVHD. Although
the small number of recipients with severe aGVHD
precluded statistical analysis of the relationship be-
tween cytokine gene polymorphisms and severe
aGVHD, the agreement between the 2 independent
cohorts suggested that TGFb12509, IL-102819,
and IL-102592 polymorphisms in the recipients or
donors were associated with the risk of aGVHD.Polymorphisms of TGFb1, TGFb1RII, and IL-10
Promoter Region Haplotype and
Transplantation Outcome
Neither among the first unrelated transplantation
cohort nor second sibling transplantation cohort was
there association between donor or recipient TGFb1
and TGFb1RII genotype and incidence of cGVHD
or extensive cGVHD. Kaplan-Meier analysis found
no significant associations between donor or recipient
TGFb1 andTGFb1RII genotypes and relapse rate, in-
cidence of death in remission, or OS (data not shown).
Table 5. Association of Cytokine Gene Polymorphisms and
aGVHD in the Second Cohort of 102 Pairs of Recipients and
Sibling Donors







T/T 7.1 .178 10.5 .229
T/C+C/C 26.1 26.5
IL102819
C/C 46.7 .042 44.4 .032
C/T+T/T 19.5 19.0
IL102592
C/C 46.7 .042 41.2 .113
C/A+A/A 19.5 20.0
aGVHD indicates acute graft-versus-host disease.
Univariate analyses of aGVHD and cytokine genotype by Fisher’s exact
tests. P-values <.1 are given in bold font.
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suggested that the IL-102819 C/C and IL-102592
C/C genotypes in either recipients or donors were sig-
nificantly associated with higher incidences of
aGVHD. Previous studies have identified linkage dis-
equilibrium between the IL-102819 SNP (T or C al-
lele) and the 2592 SNP (A or C allele), with only 2
haplotypes observed at reasonable frequencies. In 1,
2819T is linked to 2592A (the T-A haplotype), and
in the other,2819C is linked to2592C (the C-C hap-
lotype) [13]. In the combined cohort of 240 pairs of do-
nors and recipients, we stratified donors and recipients
according to promoter haplotypes of IL-10 (A-T-A, A-
C-C, and G-C-C), defined by SNPs at positions
21082, 2819, and 2592, to examine the relative ef-
fects of the individual haplotype on the risk of
aGVHD. Among the resulting genotypes, the inci-
dence of aGVHD was higher in the group without
the A-T-A haplotype than in the group with the A-
T-A haplotype, either in donors or recipients (donor
side: 71.4% versus 44.4%, P 5 .002; recipient side:
67.5% versus 45.5, P 5 .015). The same tendency
was found for the incidence of grades II–IV aGVHD
(donor side: 47.6% versus 26.8%, P 5 .01; recipient
side: 57.5% versus 25.0, P \ .001). However, the
A-T-A haplotype showed no significant protective
effect against the occurrence of cGVHD or extensive
cGVHD.
Estimates for death in remission showed a clear
advantage for recipients transplanted from donors
with the A-T-A haplotype (Figure 1A; P5 .05). Recip-
ients with the A-T-A haplotype also showed a lower
incidence of death in remission, although the difference
was not significant (Figure 1B;P5 .195).No significant
associations were found between donor or recipient
IL-10 promoter haplotypes and relapse rate or OS.Figure 1. Cumulative incidence of death in remission according to the
promoter haplotypes of IL-10 among transplantation donors (A) and re-
cipients (B) by Kaplan-Meier analysis.Multivariate Analysis of Risk Factors Associated
with aGVHD
TGFb12509 polymorphisms and IL-10 haplo-
type, together with other clinical and biological factors
known to contribute to the development of aGVHD,
were subjected to multivariate Cox proportional haz-
ard model analysis for aGVHD. The following factors
were analyzed: sibling donor versus URD, transplant
material (peripheral blood stem cells versus bone mar-
row), donor-recipient sex relation (male recipient with
female donor, or other), HLA matching, conditioning
regimen (MA conditioning versus RIC).
The results are given in Table 6. Three variables
were significantly associated with the risk of aGVHD.
MA conditioning (relative risk [RR] 5 3.423, P 5
.002), donor female and recipient male (RR 5 1.595,
P 5 .017), and URD (RR 5 4.467, P\ .001) were
found to significantly contribute to the development
of aGVHD. A donor with TGFb12509 C allele-positivity (RR5 1.436, P5 .074) and a recipient with-
out the A-T-A IL-10 haplotype (RR 5 0.764, P 5
.096) were found to be less significant factors influenc-
ing the risk of aGVHD. MA conditioning, an URD,
a donor with TGFb12509 C allele-positivity, and
a recipient without the A-T-A IL-10 haplotype also
all contributed significantly to the development of
grades II–IV aGVHD (P\ .05). A donor female and
Table 6. Multivariate Analysis of Risk Factors for aGVHD and Grades II-IV aGVHD
aGVHD Grades II-IV aGVHD
Variable RR (95%CI) P RR (95%CI) P
Myeloablative conditioning 3.423 (1.592-7.360) .002 4.764 (1.490-15.227) .008
Donor female and recipient male 1.595 (1.085-2.343) .017 1.456 (0.871-2.434) .098
Unrelated donor 4.467 (2.837-7.032) <.001 6.652 (3.538-12.509) .001
Donor with TGFb12509 C allele-positivity 1.436 (0.852-2.421) .074 2.879 (1.301-6.374) .009
Recipient without A-T-A haplotype of IL10 0.764 (0.460-1.269) .096 0.413 (0.245-0.697) .001
RR indicates relative risk; aGVHD, acute graft-versus-host disease.
548 Biol Blood Marrow Transplant 17:542-549, 2011H. Xiao et al.a recipient male was found to be a less significant factor
influencing the risk of grades II–IV aGVHD (RR 5
1.456, P 5 .098).DISCUSSION
Analyses of the outcome of the 2 separate cohorts
in the present study demonstrated a higher incidence
of aGVHD, severe aGVHD, and death in remission
in the URD transplantation cohort. OS was also
higher in the sibling transplantation cohort. We were
able to corroborate previous findings suggesting that
unrelated donor,MA conditioning, and a donor female
and a recipient male are risk factors for aGVHD. The
reduced incidence of aGVHD following RIC com-
pared toMA conditioningmay be because of less tissue
damage and lower levels of inflammatory cytokines
[14,15]. The higher incidence of aGVHD in the
URD and a female donor-to-male recipient transplan-
tation may be because of HLA and non-HLA genetic
divergence, such as sex-related Y chromosome-
encoded minor histocompatibility antigens and cyto-
kine gene polymorphisms [16-18]. Thus, HLA and
non-HLA genetics and cytokines are important factors
in the pathogenesis of aGVHD.
TGFb includesTGFb1, TGFb2, andTGFb3. The
major formexpressed in the immune systemand present
in theblood isTGFb1.TGFb1 controlsTcell tolerance
via direct inhibition of Th1, Th2, and cytotoxic T lym-
phocyte differentiation and the maintenance of Treg
cells [3]. A previous study showed that the concentration
of TGFb1 in plasma was unaffected by environmental
factors, such as age, body mass index, or drugs taken
[19]. However, the concentration of TGFb1 was genet-
ically regulated. A study of 170 pairs of female twins
found that the presence of the T allele at TGFb12509
was associated with higher concentrations of TGFb1,
and this increase in concentration was greater among
T/T homozygotes than T heterozygotes. The mean
TGFb1 concentration was approximately twice as
high in T/T compared with C/C homozygotes [20].
We found that donor TGFb12509 T/T genotype or
recipient T allele-positivity were associated with signif-
icant protective effects against aGVHD and grades
II–IV aGVHD in the unrelated transplantation cohort.
Multivariate analysis confirmed that donors withthe TGFb12509 T/T genotype reduced the risk of
aGVHD and grades II-IV aGVHD, possibly because
of higher production of the immunosuppressive cyto-
kine, TGFb1. A Japanese study of 67 pairs of children
recipients and theirHLA-identical sibling donors found
that TGFb11869 and TGFb1RII11167 polymor-
phisms were associated with the development of
aGVHD, whereas TGFb12509 genotype had no sig-
nificant influence [21]. A study in an Iranian population
also showed the association between TGFb11869
polymorphism and aGVHD [22]. The discrepancies
between the results of different studies could be because
of heterogeneity among the patients, donor type, condi-
tioning regimens, GVHD prophylaxis, or incidence of
aGVHD.
IL-10 is a well-known suppressive cytokine of
T cell proliferation and cytokine production, and
plays a pivotal role in the establishment of peripheral
T cell tolerance. Previous studies have observed an
association between elevated levels of IL-10 and re-
duced risk of aGVHD [23,24]. In both the unrelated
and sibling transplantation cohorts we found that
the IL-10–819 C/C and 2592 C/C genotypes in ei-
ther recipients or donors were significantly associated
with a higher incidence of aGVHD. In the combined
cohort, the IL-10 promoter haplotype polymor-
phisms at positions 21082, 2819, and 2592 affected
the occurrence of aGVHD and death in remission.
Recipients without the A-T-A haplotype or those
transplanted from donors without the A-T-A haplo-
type had a higher incidence of aGVHD and death in
remission than A-T-A homozygotes or heterozy-
gotes. This specific effect could be because of
increased IL-10 production in individuals with the
A-T-A haplotype, as previously reported [13,25,26].
A study of 570 pairs of transplant recipients and
their HLA-identical sibling donors also demonstrated
that the A-T-A haplotype was associated with a lower
risk of aGVHD [13], although the same study group
failed to observe the samilar effects in a cohort of
patients and their unrelated donors [27].
In the current study, no significant associations
were found between cytokine gene polymorphisms
and cGVHD, relapse, or OS. This could be because
of differences in the pathophysiology of aGVHD and
cGVHD and stronger immunosuppressive therapy in
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correlation between cytokine gene polymorphisms and
cGVHD. Numerous influences could affect the re-
lapse andOS rates and reduce the influence of cytokine
gene polymorphisms.
The results of previous studies of non-HLA immu-
nogenetics, including cytokine gene polymorphisms, in
HSCT have been inconsistent. Specialists have concen-
trated on the influences of patient heterogeneity, condi-
tioning regimens, and GVHD prophylaxis. However,
significant differences in the occurrence of aGVHDbe-
tween different cohorts, as between our 2 independent
cohorts, could also contribute to the inconsistencies.
The association may become more apparent if groups
at higher risk of GVHD are studied, as in unrelated
or mismatched donor transplantation.
This study is first to report the relationship be-
tween IL-10, TGFb1, and TGFb1RII polymorphisms
and the outcome of allo-HSCT within the Chinese
population. The results may provide useful informa-
tion for determining risk assessment and donor selec-
tion, and as a guide for selecting appropriate
immunosuppressive therapy.ACKNOWLEDGMENTS
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